Unit:
Κατεύθυνση Έγκαιρη Παρέμβαση στην ΨύχωσηLibrary of the School of Health Sciences
Author:
Spyropoulou Charikleia
Supervisors info:
Στεφανής Νικόλαος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ, Επιβλέπων
Πέτρος Λέκκος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Λήδα-Άλκηστις Ξενάκη, Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Η χρήση φαρμακευτικής κάνναβης στην ψύχωση: εφαρμογές και πιθανές παγίδες
Translated title:
The use of medicinal cannabis in psychosis: applications and potential risks
Summary:
This systematic review evaluates the therapeutic effectiveness of cannabidiol (CBD) in the treatment of early psychosis, an alternative therapy that has gained significant interest in recent years. It specifically examines the neuroprotective, anxiolytic, and antipsychotic characteristics of CBD, including evaluations of its efficacy in alleviating psychotic symptoms and enhancing cognitive performance. This study consolidates results from 28 trials, research, investigations, or reviews undertaken in the preceding decade since 2013 until today. Furthermore, evidence indicates that therapeutic cannabis may alleviate specific adverse effects linked to cannabis usage in patients with psychosis, especially among those who simultaneously consume cannabis. Nonetheless, the data about its long-term efficacy remain incongruous due to the scarcity of studies, which have just recently begun to proliferate. Although preliminary findings are encouraging, larger and more standardized clinical trials are necessary to further explore and elucidate its therapeutic efficacy in early psychosis, particularly during the initial psychotic episode. This review advocates for subsequent clinical investigations to further examine CBD as a possibly safer and more efficacious medicinal option.
Main subject category:
Health Sciences
Keywords:
Τherapeutic Cannabidiol (CBD), First Psychotic Episode (FEP), Therapeutic Cannabis In Early Psychosis, CBD In Early-onset Psychosis
